Goodwill

The Company tests goodwill for impairment annually as of October 1 or more frequently if impairment indicators arise at the reporting unit level, which is the operating segment or one level below an operating segment. The Company has the option of performing a qualitative assessment to determine whether further impairment testing is necessary before performing the quantitative assessment. If, as a result of the qualitative assessment, it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount, a quantitative impairment test will be required.

On April 1, 2026, the Company completed the merger of the Bruker Cellular Analysis (“BCA”) business into the Bruker Spatial Biology (“BSB”) division. In connection with this merger, the Company performed a goodwill impairment test for the BSB reporting unit pre‑merger as of March 31, 2026, and for the newly combined BSB reporting unit post‑merger as of April 1, 2026. Based on the results of the post-merger goodwill impairment test, during the three and six months ended June 30, 2026, the Company recorded a goodwill impairment charge of $36.5 million in the unaudited condensed consolidated statements of operations within the BSI NANO segment, which represented the amount by which the carrying value of the post-merger BSB reporting unit exceeded its fair value.

During the three months ended June 30, 2026, the Company reduced its forecasted revenue and cash flows for the CST (formerly Automation) reporting unit. As a result, the Company performed a goodwill impairment test for the CST reporting unit. During the three and six months ended June 30, 2026, the Company recorded a goodwill impairment charge of $98.4 million in the unaudited condensed consolidated statements of operations within the BSI BioSpin segment, which represented the remaining goodwill balance of the CST reporting unit.

In determining the fair value of the CST reporting unit, the Company used the income approach. Significant assumptions in the discounted cash flow model included, but were not limited to, a discount rate of 13.5%, revenue growth and operating margin assumptions at the lower end of the projected ranges for the Company’s other significant businesses.

In determining the fair value of the BSB reporting unit, the Company used a weighted combination of the market approach and the income approach. Significant assumptions in the discounted cash flow model included, but were not limited to, a discount rate of 14.0%, revenue growth and operating margin rate assumptions at the higher end of the projected ranges for the Company’s other significant businesses.

The assumptions used in our impairment analyses were developed in light of current market conditions and future expectations which included, but were not limited to, new product and service developments, impact of competition, and future economic conditions.

As described in Note 1, Description of Business, subsequent to June 30, 2026, the Company completed a reorganization of its reportable segments. This reorganization resulted in changes to the composition of certain of the Company's reporting units and constitutes a triggering event requiring an interim goodwill impairment analysis. The Company expects to complete the analysis during the third quarter with charges, if any, recorded in that period. Additionally, the Company will continue to monitor circumstances and uncertainties that may impact the carrying values of its reporting units, including the current macroeconomic conditions and the timing and quantity of future cash flows. If the fair value of any of the Company’s reporting units declines below the carrying value in future periods, additional goodwill impairment charges may be incurred.

Intangible Assets

For the three months ended June 30, 2026, and 2025, the Company recorded amortization expense of $33.3 million and $31.5 million, respectively, related to intangible assets subject to amortization. For the six months ended June 30, 2026, and 2025, the Company recorded amortization expense of $65.8 million and $58.8 million, respectively, related to intangible assets subject to amortization.

On a quarterly basis, the Company reviews its intangible assets to determine if there have been any triggering events that could indicate an impairment. Impairment losses are recorded when indicators of impairment are present and the quoted market price, if available or the estimated fair value of those assets are less than the assets’ carrying value, and are not recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. Impairment costs are recorded in total cost of revenue and total operating expenses in the unaudited condensed consolidated statements of operations for the difference between the fair value and carrying value of the asset. During the three and six months ended June 30, 2026, the Company identified indicators of impairment due to the operating performance of certain asset groups and the decision to discontinue certain product lines due to restructurings plans as described in Note 10, Restructuring and Asset Impairments. In connection therewith, the Company determined that certain long-lived assets had net carrying values that were not recoverable and as a result, during the first quarter of 2026, the Company recorded a de-minimis impairment charge to write off certain existing technology and related patents intangible assets. No intangible asset impairment charges were required as a result of the goodwill impairment triggering events identified for the BSB and CST reporting units, and there were no intangible asset impairment charges recorded during the second quarter of 2026. During the three and six months ended June 30, 2025, the Company recognized impairment charges of $6.8 million and $7.2 million, respectively, to write off certain intangible assets.